About: Evidence for lung repair and regeneration in humans: key stem cells and therapeutic functions of fibroblast growth factors

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evidence for lung repair and regeneration in humans: key stem cells and therapeutic functions of fibroblast growth factors Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evidence for lung repair and regeneration in humans: key stem cells and therapeutic functions of fibroblast growth factors
Creator	Li, Xiaokun Bellusci, Saverio Chen, Chaolei Chen, Chengshui Chu, Xuran Zhang, Jin-San
Source	PMC
abstract	Regeneration carries the idea of regrowing partially or completely a missing organ. Repair, on the other hand, allows restoring the function of an existing but failing organ. The recognition that human lungs can both repair and regenerate is quite novel, the concept has not been widely used to treat patients. We present evidence that the human adult lung does repair and regenerate and introduce different ways to harness this power. Various types of lung stem cells are capable of proliferating and differentiating upon injury driving the repair/regeneration process. Injury models, primarily in mice, combined with lineage tracing studies, have allowed the identification of these important cells. Some of these cells, such as basal cells, broncho-alveolar stem cells, and alveolar type 2 cells, rely on fibroblast growth factor (FGF) signaling for their survival, proliferation and/or differentiation. While preclinical studies have shown the therapeutic benefits of FGFs, a recent clinical trial for acute respiratory distress syndrome (ARDS) using intravenous injection of FGF7 did not report the expected beneficial effects. We discuss the potential reasons for these negative results and propose the rationale for new approaches for future clinical trials, such as delivery of FGFs to the damaged lungs through efficient inhalation systems, which may be more promising than systemic exposure to FGFs. While this change in the administration route presents a challenge, the therapeutic promises displayed by FGFs are worth the effort.
has issue date	2019-11-18(xsd:dateTime)
bibo:doi	10.1007/s11684-019-0717-5
bibo:pmid	31741137
has license	no-cc
sha1sum (hex)	2abf2bec88817e4e43ef15f0dd7651f96a0f86df
schema:url	https://doi.org/10.1007/s11684-019-0717-5
resource representing a document's title	Evidence for lung repair and regeneration in humans: key stem cells and therapeutic functions of fibroblast growth factors
has PubMed Central identifier	PMC7095240
has PubMed identifier	31741137
schema:publication	Front Med
resource representing a document's body	covid:2abf2bec88817e4e43ef15f0dd7651f96a0f86df#body_text
is schema:about of	named entity 'patients' named entity 'adult' named entity 'The recognition' named entity 'While' named entity 'cells' named entity 'repair' named entity 'clinical trial' named entity 'FGF' named entity 'FGF7' named entity 'THESE' named entity 'DISCUSS' named entity 'STUDIES' named entity 'HAVE' named entity 'CLINICAL TRIALS' named entity 'THERAPEUTIC' named entity 'STEM CELLS' named entity 'LUNG' named entity 'DIFFERENT' named entity 'route' named entity 'regenerate' named entity 'intravenous injection' named entity 'reasons' named entity 'growth factor' named entity 'stem cells' named entity 'human' named entity 'systems' named entity 'rely' named entity 'partially' named entity 'Various' named entity 'basal cells' named entity 'mice' named entity 'type 2' named entity 'lungs' named entity 'FGFs' named entity 'FGFs' named entity 'alveolar' named entity 'fibroblast growth factor' named entity 'lungs' named entity 'treat patients' named entity 'lung' named entity 'fibroblast growth factors' named entity 'forced vital capacity' named entity 'homolog' named entity 'bleomycin' named entity 'Gprc5a' named entity 'clinical trial' named entity 'organoid' named entity 'Fgf10' named entity 'Fgf' named entity 'FGF7' named entity 'muscle' named entity 'bronchoalveolar' named entity 'human lung' named entity 'lung development' named entity 'distal' named entity 'protein' named entity 'lungs' named entity 'Tlr2' named entity 'alveolar' named entity 'molecular mechanisms' named entity 'lungs' named entity 'intravenously' named entity 'acute respiratory distress syndrome' named entity 'early development' named entity 'clinical trials' named entity 'progenitor cells' named entity 'lung function' named entity 'developmental pathways' named entity 'keratinocyte growth factor' named entity 'FGF' named entity 'salivary glands' named entity 'ontogenesis' named entity 'perfused' named entity 'respiratory functions' named entity 'radiotherapy' named entity 'lungs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software